Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells

References

• Davie JR. Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin. Mol Biol Rep 1997; 24:197 - 207; http://dx.doi.org/10.1023/A:1006811817247; PMID: 9291093
   PubMed Web of Science ®Google Scholar
• Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389:349 - 52; http://dx.doi.org/10.1038/38664; PMID: 9311776
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074 - 80; http://dx.doi.org/10.1126/science.1063127; PMID: 11498575
   PubMed Web of Science ®Google Scholar
• Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem Cell Biol 2005; 83:344 - 53; http://dx.doi.org/10.1139/o05-041; PMID: 15959560
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91:137 - 68; http://dx.doi.org/10.1016/S0065-230X(04)91004-4; PMID: 15327890
   PubMed Web of Science ®Google Scholar
• Buchwald M, Krämer OH, Heinzel T. HDACi--targets beyond chromatin. Cancer Lett 2009; 280:160 - 7; http://dx.doi.org/10.1016/j.canlet.2009.02.028; PMID: 19342155
   PubMed Web of Science ®Google Scholar
• Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278:1059 - 64; http://dx.doi.org/10.1126/science.278.5340.1059; PMID: 9353180
   PubMed Web of Science ®Google Scholar
• Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol 1999; 106:296 - 308; http://dx.doi.org/10.1046/j.1365-2141.1999.01377.x; PMID: 10460585
   PubMed Web of Science ®Google Scholar
• Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87:953 - 9; http://dx.doi.org/10.1016/S0092-8674(00)82001-2; PMID: 8945521
   PubMed Web of Science ®Google Scholar
• Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 1998; 17:2994 - 3004; http://dx.doi.org/10.1093/emboj/17.11.2994; PMID: 9606182
   PubMed Web of Science ®Google Scholar
• Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18:7185 - 91; PMID: 9819405
   PubMed Web of Science ®Google Scholar
• Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 1998; 95:10860 - 5; http://dx.doi.org/10.1073/pnas.95.18.10860; PMID: 9724795
   PubMed Web of Science ®Google Scholar
• Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 2003; 17:350 - 8; http://dx.doi.org/10.1038/sj.leu.2402776; PMID: 12592335
   PubMed Web of Science ®Google Scholar
• Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 2005; 65:1277 - 84; http://dx.doi.org/10.1158/0008-5472.CAN-04-4532; PMID: 15735013
   PubMed Web of Science ®Google Scholar
• Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 2007; 321:953 - 60; http://dx.doi.org/10.1124/jpet.106.118406; PMID: 17389244
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106:112 - 9; http://dx.doi.org/10.1002/cncr.21552; PMID: 16323176
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114:2764 - 73; http://dx.doi.org/10.1182/blood-2009-02-203547; PMID: 19546476
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459 - 68; http://dx.doi.org/10.1200/JCO.2009.22.1291; PMID: 19826124
   PubMed Web of Science ®Google Scholar
• Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009; 20:1293 - 302; http://dx.doi.org/10.1093/annonc/mdn792; PMID: 19515748
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16:1111 - 20; http://dx.doi.org/10.1517/13543784.16.7.1111; PMID: 17594194
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84 - 90; http://dx.doi.org/10.1038/nbt1272; PMID: 17211407
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25:226 - 35; http://dx.doi.org/10.1038/leu.2010.276; PMID: 21116282
   PubMed Web of Science ®Google Scholar
• Gozzini A, Rovida E, Dello Sbarba P, Galimberti S, Santini V. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Res 2003; 63:8955 - 61; PMID: 14695213
   PubMed Web of Science ®Google Scholar
• Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008; 27:1767 - 78; http://dx.doi.org/10.1038/sj.onc.1210820; PMID: 17891169
   PubMed Web of Science ®Google Scholar
• Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007; 8:383 - 93; http://dx.doi.org/10.2174/138920007780655397; PMID: 17504226
   PubMed Web of Science ®Google Scholar
• Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 2003; 101:270 - 7; http://dx.doi.org/10.1182/blood-2002-04-1288; PMID: 12393465
   PubMed Web of Science ®Google Scholar
• Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7:444 - 51; http://dx.doi.org/10.1038/86515; PMID: 11283671
   PubMed Web of Science ®Google Scholar
• Rovida E, Gozzini A, Barbetti V, Giuntoli S, Santini V, Dello Sbarba P. The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells. Br J Haematol 2006; 135:653 - 9; http://dx.doi.org/10.1111/j.1365-2141.2006.06365.x; PMID: 17054427
   PubMed Web of Science ®Google Scholar
• Tenen DG. Disruption of differentiation in human cancer: AML shows the way. [Review] Nat Rev Cancer 2003; 3:89 - 101; http://dx.doi.org/10.1038/nrc989; PMID: 12563308
   PubMed Web of Science ®Google Scholar
• Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005; 104:2717 - 25; http://dx.doi.org/10.1002/cncr.21589; PMID: 16294345
   PubMed Web of Science ®Google Scholar
• Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006; 66:8903 - 11; http://dx.doi.org/10.1158/0008-5472.CAN-05-2726; PMID: 16951208
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541 - 52; http://dx.doi.org/10.1038/sj.onc.1210620; PMID: 17694093
   PubMed Web of Science ®Google Scholar
• Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64:1079 - 86; http://dx.doi.org/10.1158/0008-5472.CAN-03-0799; PMID: 14871841
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459 - 68; http://dx.doi.org/10.1200/JCO.2009.22.1291; PMID: 19826124
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391 - 400; http://dx.doi.org/10.1038/ng1531; PMID: 15765097
   PubMed Web of Science ®Google Scholar
• Hajji N, Wallenborg K, Vlachos P, Füllgrabe J, Hermanson O, Joseph B. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. Oncogene 2010; 29:2192 - 204; http://dx.doi.org/10.1038/onc.2009.505; PMID: 20118981
   PubMed Web of Science ®Google Scholar
• Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76:75 - 100; http://dx.doi.org/10.1146/annurev.biochem.76.052705.162114; PMID: 17362198
   PubMed Web of Science ®Google Scholar
• Xie W, Song C, Young NL, Sperling AS, Xu F, Sridharan R, et al. Histone h3 lysine 56 acetylation is linked to the core transcriptional network in human embryonic stem cells. Mol Cell 2009; 33:417 - 27; http://dx.doi.org/10.1016/j.molcel.2009.02.004; PMID: 19250903
   PubMed Web of Science ®Google Scholar
• Zhang L, Su X, Liu S, Knapp AR, Parthun MR, Marcucci G, et al. Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry. J Proteome Res 2007; 6:81 - 8; http://dx.doi.org/10.1021/pr060139u; PMID: 17203951
   PubMed Web of Science ®Google Scholar
• Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 2001; 20:5660 - 79; http://dx.doi.org/10.1038/sj.onc.1204593; PMID: 11607817
   PubMed Web of Science ®Google Scholar
• Dion MF, Altschuler SJ, Wu LF, Rando OJ. Genomic characterization reveals a simple histone H4 acetylation code. Proc Natl Acad Sci U S A 2005; 102:5501 - 6; http://dx.doi.org/10.1073/pnas.0500136102; PMID: 15795371
   PubMed Web of Science ®Google Scholar
• Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006; 311:844 - 7; http://dx.doi.org/10.1126/science.1124000; PMID: 16469925
   PubMed Web of Science ®Google Scholar
• Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447:407 - 12; http://dx.doi.org/10.1038/nature05915; PMID: 17522673
   PubMed Web of Science ®Google Scholar
• Robinson PJ, An W, Routh A, Martino F, Chapman L, Roeder RG, et al. 30 nm chromatin fibre decompaction requires both H4-K16 acetylation and linker histone eviction. J Mol Biol 2008; 381:816 - 25; http://dx.doi.org/10.1016/j.jmb.2008.04.050; PMID: 18653199
   PubMed Web of Science ®Google Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286 - 98; http://dx.doi.org/10.1038/nrg2005; PMID: 17339880
   PubMed Web of Science ®Google Scholar
• Brookes E, Pombo A. Modifications of RNA polymerase II are pivotal in regulating gene expression states. EMBO Rep 2009; 10:1213 - 9; http://dx.doi.org/10.1038/embor.2009.221; PMID: 19834511
   PubMed Web of Science ®Google Scholar
• Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010; 62:18 - 34; http://dx.doi.org/10.1016/j.phrs.2010.02.010; PMID: 20219679
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11:77 - 84; http://dx.doi.org/10.1038/nm1161; PMID: 15619633
   PubMed Web of Science ®Google Scholar
• Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20:6969 - 78; http://dx.doi.org/10.1093/emboj/20.24.6969; PMID: 11742974
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, et al. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Ann Hematol 2006; 85:689 - 704; http://dx.doi.org/10.1007/s00277-006-0148-7; PMID: 16832676
   PubMed Web of Science ®Google Scholar
• Zapotocky M, Mejstrikova E, Smetana K, Stary J, Trka J, Starkova J. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically. Cancer Lett 2012; 319:144 - 53; http://dx.doi.org/10.1016/j.canlet.2011.12.041; PMID: 22261333
   PubMed Web of Science ®Google Scholar
• Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77:2031 - 6; PMID: 2018839
   PubMed Web of Science ®Google Scholar
• Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77:1080 - 6; PMID: 1995093
   PubMed Web of Science ®Google Scholar
• Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26:171 - 6; http://dx.doi.org/10.1002/ijc.2910260208; PMID: 6970727
   PubMed Web of Science ®Google Scholar
• Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3:166 - 79; PMID: 21416059
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402 - 8; http://dx.doi.org/10.1006/meth.2001.1262; PMID: 11846609
   PubMed Web of Science ®Google Scholar